EMA cites Micro Labs plant in India

The European Medicines Agency has cited a Micro Labs plant in India that makes capsules. (Pixabay)

The European Medicines Agency has found issues at the plant of an Indian API maker that the FDA hit with a warning letter some years back.

In a recent posting, the EMA noted a risk of cross contamination of products during a November inspection by the U.K. of a Micro Labs plant in Hosur, India. The plant produces tablets and capsules, the agency noted.

RELATED: FDA letter takes issue with Micro Labs' data practices


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

While only the one violation was cited, regulators found the problem severe enough to withdraw the company’s GMP certificate for the plant and suggest that countries recall its products if they are not essential to patient supply. The agency also is prohibiting any new products for which there are alternatives.

The FDA in 2015 cited a Micro Labs plant in Bangalore with a warning letter, mostly for data integrity concerns. According to the FDA, Micro Labs personnel failed to ensure laboratory records included complete data, to exercise appropriate controls over computer systems and record or to justify any deviations from required laboratory control mechanisms.

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.